Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $80,733.10 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the completion of the sale, the insider directly owned 4,784,111 shares of the company’s stock, valued at approximately $4,640,587.67. This trade represents a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, December 3rd, Bioventures 2014 L.P. Mpm sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $49,785.75.
• On Tuesday, December 2nd, Bioventures 2014 L.P. Mpm sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $52,756.53.
• On Monday, December 1st, Bioventures 2014 L.P. Mpm sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $57,261.98.
• On Friday, November 28th, Bioventures 2014 L.P. Mpm sold 20,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $20,074.23.
• On Wednesday, November 26th, Bioventures 2014 L.P. Mpm sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total transaction of $59,518.34.
• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $87,025.96.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ HOWL traded up $0.08 during midday trading on Thursday, reaching $1.00. 587,802 shares of the company were exchanged, compared to its average volume of 504,491. The stock has a market cap of $48.36 million, a P/E ratio of -0.61 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38. The stock has a fifty day simple moving average of $1.42 and a 200 day simple moving average of $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOWL has been the subject of several recent research reports. JMP Securities decreased their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Bank of America cut their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC lifted its stake in shares of Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC raised its stake in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the period. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the first quarter worth about $71,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $92,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.